|1.||Kohonen, P: 1 article (07/2014)|
|2.||Kallioniemi, O: 1 article (07/2014)|
|3.||Fey, V: 1 article (07/2014)|
|4.||Kaminskyy, V O: 1 article (07/2014)|
|5.||Zhivotovsky, B: 1 article (07/2014)|
|6.||He, T: 1 article (07/2014)|
|7.||Haapa-Paananen, S: 1 article (07/2014)|
|8.||Perälä, M: 1 article (07/2014)|
|9.||Vyas, V K: 1 article (10/2011)|
|10.||Ghate, M: 1 article (10/2011)|
07/03/2014 - "Furthermore, several other cancer cell lines, LNCaP, MCF-7 and HT-29 were also shown to be sensitized to TRAIL by brequinar. "
01/01/1992 - "Brequinar is such an inhibitor that has little clinical anti-tumor effect when used alone. "
02/01/1990 - "In two tumor lines DHO-DH activity could be measured and the results are in agreement with the concept that there is a relation between Brequinar sodium sensitivity and enzyme activity."
01/01/1990 - "Two tumor models were used, Colon 26 and Colon 38, resistant and moderately sensitive to DUP-785, respectively. "
01/01/1988 - "Within 1 h Brequinar distributed to the tumor and all other tissues studied. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
01/01/1990 - "Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC."
01/01/1987 - "Among 22 investigational compounds, currently being investigated in phase I or early phase II clinical trials, we found that trimetrexate, DUP-785, didemnin-B, and flavone-8-acetic acid might be effective for treatment of patients with colorectal cancer."
01/01/1988 - "Our results suggest that trimetrexate, DUP-785, didemnin B, and flavone-8-acetic acid may be clinically effective for the treatment of colorectal cancer."
|3.||Melanoma (Melanoma, Malignant)
09/01/1992 - "Multicenter phase II trial of brequinar sodium in patients with advanced melanoma."
09/01/1992 - "We conclude that, at this dose and schedule, brequinar has no activity in advanced melanoma."
09/01/1992 - "Seventeen patients with advanced melanoma and no prior exposure to chemotherapy were treated with brequinar sodium as first-line chemotherapy. "
01/01/1987 - "First, we studied growth inhibition by DUP-785 in L1210 leukemia cells and M5 melanoma cells. "
|4.||Lung Neoplasms (Lung Cancer)
|5.||Gastrointestinal Neoplasms (Gastrointestinal Cancer)
|3.||flavone acetic acid
|5.||Carrier Proteins (Binding Protein)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Homologous Transplantation (Allograft)